We examined the cellular effects of topo II inhibitors in two human myeloid cell lines, HL-60 and KG-1 cells, with the purpose of finding molecular markers for the sensitivity of leukemia cells to topo II inhibitors. These cell lines are widely used, well characterized and they differ in their sensitivities to topo II inhibitors. Despite the fact that HL-60 cells are p53-negative, they are much more sensitive than KG-1 cells. Three different topo II inhibitors with distinct molecular ways of action have been used. Daunorubicin and aclarubicin are DNA intercalators that secondarily interact with topo II; etoposide, on the other hand, directly binds to the enzyme. In contrast to daunorubicin, which induces protein-associated DNA double-strand breaks due to the blockage of topo II action, aclarubicin inhibits the access of DNA by topo II. No correlation could be established between the drug-induced DNA damage and apoptosis. In fact, the amount and pattern of DNA damage examined with the 'comet assay' was characteristic for each drug in both cell lines. The DNA binding of daunorubicin was slightly higher in HL-60 cells, but there was no notable variance between the cell lines for aclarubicin. The most striking difference could be found for the nuclear topo II activity, which was about half in KG-1 cells and, additionally, less than 1% of the nuclear topo II activity was bound to the DNA in KG-1 cells when compared to HL-60 cells. This fraction of topo II interacts with the inhibitors; subsequently these findings might well explain the variance in the cellular sensitivity. Additional factors are alterations of the apoptotic pathways, eg loss of p53 in HL-60 cells. Although we found no differences in the quantity of DNA damage between the cell lines after drug treatment, the quality of DNA damage appeared to be distinct for each topo II inhibitor. The morphological appearance of the comet tails after treatment was characteristic for each drug. Further studies are necessary to decide whether these in vitro data are compatible with the clinical situation.
Introduction
Topoisomerase II (topo II) inhibitors are the backbone of most hemato-oncological strategies, although the molecular events that result in apoptotic cell death are still unveiled. Anthracyclines and epipodophyllotoxines use different ways to inhibit the DNA processing enzyme topo II; whereas anthracyclines are intercalators and secondarily interact with topo II, epipodophyllotoxines bind directly to the enzyme. 1, 2 Both types of inhibitors block the action of topo II after the induction of DNA double-strand breaks. This results in DNA damage with covalent binding of topo II to the DNA ends. 3 It is widely accepted that the combination of protein-associated DNA damage with the loss of the enzyme's activity ultimately induces cell death. However, a number of observations are Correspondence: F Gieseler, Klinik fü r Allgemeine Innere Medizin der Christian-Albrechts-Universität, Schwerpunkt Hämatologie/ Onkologie, Schittenhelmstrasse 12, 24105 Kiel, Germany; Fax: +431 597 1302 Received 12 August 1998; accepted 12 July 1999 not consistent with this model. Resistant cells ultimately develop mechanisms that allow for surviving DNA damage induced by anthracyclines. [4] [5] [6] In addition to DNA damage, other apoptosis mechanisms such as the CD95/FAS-pathway seem to be important. Friesen et al 7 have shown that blockage of the CD95-receptor inhibits daunorubicin-induced apoptosis. Aclarubicin, on the other hand, is also able to induce apoptosis although no topo II/DNA complex is formed. In contrast to the classical anthracyclines such as daunorubicin or doxorubicin, aclarubicin inhibits the access of topo II to the DNA. A number of clinical studies have proven the effectiveness of aclarubicin in the therapy of AML. [8] [9] [10] [11] [12] Several different apoptosis pathways, including the activation of p53, involvement of the CD-95/FAS-pathway, tumor necrosis factor or cytochrome-C release by mitochondria, have been proposed. 13 Obviously, the pathways that are utilized are specific for different cell types. The induction of the CD-95/FAS-system by daunorubicin for example, seems to be a preferred mechanism in lymphatic cells, but not in myeloblastic leukaemia cells. 7, 14, 15 The development of cellular resistance is a major problem in the therapy of AML. The elaboration of therapeutic strategies to recognize and overcome cellular resistance requires the knowledge of the molecular determinants for response to the therapy with topo II inhibtors. In this paper, the intracellular effects of etoposide, daunorubicin and aclarubicin have been examined using two different human myeloblastic cell lines. HL-60 and KG-1 cells were selected because they are widely used and well-characterized cell lines, and they exhibit major differences in their sensitivity to topo II inhibitors.
Materials and methods

Cell lines
HL-60 cells (ATCC 45500) were cultured in RPMI 1640, 25 mM HEPES (Sigma, St Louis, MO, USA) with 2 mM L-glutamine, penicillin/streptamycin, and 7.5% FCS (Gibco, Grand Island, NY, USA). KG-1 cells (ATCC CRL-8031) were cultured in Iscove's modified Dulbecco's medium (Sigma) with 2 mM L-glutamine, 20% FCS (Gibco). Cultures were incubated in the presence of 5% CO 2 in a water-jacketed incubator (Forma Scientific, Germany).
Topoisomerase II inhibitors
Drug concentrations were the same for all experiments: etoposide (Bristol-Myers Squibb, Munich, Germany) 1 g/ml; daunorubicin (Pharmacia and Upjohn, Erlangen, Germany) 0.1 g/ml; aclarubicin (MEDAC, Hamburg, Germany) 0.1 g/ml. Due to the high protein-binding of anthracyclines it is mandatory to use the same extracellular protein concentrations for toxicological tests.
Alamar blue assay
200 l cell suspension with 2.5 × 10 5 cells/ml were incubated at 37°C for in the presence of drugs for 72 h on 96-well flatbottom tissue culture plates with low evaporation lids (Costar, Bodenheim, Germany). Then 25 l/well Alamar blue (BioSource, Ratingen, Germany) was added and the cells incubated for an additional 18 h at 37°C. The fluorescence was subsequently measured on a LS50B luminescence spectrometer (Perkin Elmer, Konstanz, Germany) with excitation at 540 nM and emission at 590 nM. The IC 50 and IC 90 concentrations were calculated from the arbitrary units using the control measurements for 0% proliferation (medium without cells) and 100% (cell suspension without drugs).
DNA binding of drugs in intact cells
Two ml cell suspension with 2.5 × 10 5 cells/ml were incubated at 37°C for 30 min in HBSS containing 6.25 g/ml Hoechst dye 33342 (Hoechst, Bad Soden, Germany). After addition of drugs, the cells were incubated at 37°C for an additional 30 min. Quenching of Hoechst-dye fluorescence was subsequently measured using a Partec flow-cytometer.
Apo-2.7 detection
Cells were incubated with drugs for 1 h, then washed and resuspended in complete medium for 24 h. 5 × 10 5 cells then were washed with PBS and permeabilized with 100 l ice cold digitonin (100 g/ml) dissolved in PBS supplemented with 2.5% FCS and 0.01% NaN 3 for 20 min on ice. After washing the pellet, 10 l of the MoAb Apo2.7-PE (Coulter Immunotech, Marseille, France) or an isotype-matched control were added and gently mixed. Cells were incubated for 15 min at room temperature in the dark, washed and analyzed on a FACScan flow cytometer with Cell Quest software (Becton Dickenson, Heidelberg, Germany). 
CD95 expression
Drug-induced DNA damage
The single cell microgel electrophoresis assay ('comet assay'):
Cells were cultured for 3 h with or without drugs, then centrifuged and re-suspended in fresh medium without drugs and incubated for an additional 21 h at 37°C before being prepared for electrophoresis. 5 × 10 4 cells in 75 l 1% low melting point agarose (Sigma) were sandwiched between two layers of agarose, 85 l 0.5% NEEO agarose (Roth, Deisenhofen, Germany) for the foundation layer on the slide and 75 l 1% low melting point agarose for the upper layer. The agarose slides are then lysed in 1% Triton X-100, 10% DMSO (Sigma) and 89% lysis buffer, pH 10 (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% N-laurylsarcosine sodium salt for at least 1 h. The agarose slides are equilibrated for 20 min in electrophoresis buffer (300 mM NaOH and 1 mM EDTA, pH Ͼ12.5) and subsequently the electrophoresis is run at 25 volts and 300 milliampere for 20 min. The slides were neutralized in several changes of 0.4 M Tris, pH 7.5 and the DNA stained with 50 l of 20 g/ml ethidium bromide solution. The cells were catalogued using a fluorescence microscope and photographed. Cells with DNA tails longer than one diameter of the nucleus were calculated as positive for DNA damage.
Topoisomerase II activity 2.5 × 10 5 cells/ml were incubated with the desired drug concentrations for 3 h. Subsequently the nuclei were isolated on ice with 8 ml lysis buffer (0.3 M sucrose; 0.5 mM EGTA, pH 8.0; 60 mM KCl; 15 mM NaCl; 15 mM HEPES, pH 7.5; 150 M spermidine (Sigma) +40 l Triton X-100). The nuclei were counted and washed in lysis buffer without Triton X-100. The nuclei pellet was re-suspended in extraction buffer (5 mM KPhosphate, pH 7.5; 100 mM NaCl (Roth); 1 l/ml 2-mercatoethanol; 5 l/ml 200 mM PMSF (Sigma) at a concentration of 3 × 10 7 nuclei/ml. 90 l 5 M NaCl/ml extraction buffer was added (350 mM) and the tube mixed by inverting. After 15 min on ice, the DNA and undissolved protein was pelleted by centrifugation, 12 000 g for 10 min. The DNA/protein pellet was removed from the extract to a new tube and the same amount of extraction buffer was added as in the previous step. Reextraction to determine the fraction of DNA-bound topoisomerase activity was then done with 900 mM NaCl (200 l/ml extraction buffer). Both first and second extracts were stored at −20°C in 50% glycerol.
Topoisomerase II activity was quantified using a modification of a standard relaxation assay as published before: 16, 17 1 g pBR 322 supercoiled plasmid DNA was relaxed with nuclear extracts using assay buffers (0.5 M bis-tris-propane; 900 mM L-glutamic acid, monopotassium salt; 5 mM MgCl 2 . 75 g/ml BSA; 10 mM ATP, 50 mM DTT) with an adjusted pH of 8.9. Topo I activity was inhibited by the addition of 1 M camptothecin. The gels were stained with ethidium bromide and photographed with Polaroid 667 black and white film. The photos were scanned with an Apple One Scanner and a grey-scale analysis performed. One unit is defined as being the amount of activity from 1 × 10 4 nuclei required to relax 90% of 500 ng DNA.
Results
In this paper, the cellular effects of topoisomerase II inhibitors in two different cell lines have been compared. HL-60 cells and KG-1 cells are widely used human myeloblastic cell lines. Some characteristics of these cells are shown in Table 1 . HL-60 cells had a doubling time of 22.2 h; KG-1 cells in contrast needed 64.1 h to duplicate as displayed in Table 1 .
DNA binding of drugs and induction of apoptosis
In contradiction to the loss of p53, HL-60 cells are much more sensitive to topoisomerase II inhibitors as KG-1 cells (Table 2) . In addition to the alamar blue assay which has been used for the experiments presented in Table 2 , cell death had been estimated by trypan blue exclusion, with very similar data. Alterations of the mitochondrial membrane that are characteristic for apoptotic cell death, were detected by the appearance of Apo-2.7 (Table 3 ). Due to its high fluorescence, daunorubicin could not be analyzed in this setting. In both cell types, daunorubicin as well as aclarubicin had high DNA binding rates ( Table 4 ). The DNA binding rate of daunorubicin was considerably higher in HL-60 cells than in KG-1 cells. We did not find these differences for aclarubicin (Table 4) . 
Figure 1
Free and DNA-bound topo II activity in nuclear extracts 21 h after a 3-h treatment shown as percentage of total activity (median of three experiments, ±s.d.). ctr, control; eto, etoposide; dau, daunorubicin; acla, aclarubicin.
Topo II activity before and after treatment
The topo II activity in the nuclei of KG-1 cells was almost half the activity in HL-60 nuclei (Table 5) . Moreover, only 0.32% of the total topo II activity in KG-1 cells was DNA-bound (Table 5 ). After incubation of the cells with topo II inhibitors, the shift in the relation between free and DNA-bound topo II activity has been measured. As shown in Figure 1 , etoposide as well as daunorubicin increased the relation of DNA-bound to free activity. Incubation of the cells with aclarubicin in contrast, reduced the DNA-bound fraction in HL-60 cells and resulted in only a slight increase in KG-1 cells. For the interpretation of the results, the lower total activity and the low fraction of DNA-bound activity in untreated KG-1 cells must be taken into consideration.
Nuclear swelling and DNA damage after treatment
It has been suggested that the DNA damage after treatment with topo II inhibitors is an important factor for the induction of apoptosis. [18] [19] [20] We did not find notable differences between the sensitive HL-60 cells and the more resistant KG-1 cells (Figure 2 ), 21 h after a 3-h treatment. As well as daunorubicin,
Figure 2
DNA damage 21 h after a 3-h treatment shown as a fraction of cells with comets longer than the diameter of the nucleus (%), median of three to four experiments, ±s.d.). Abbreviations as Figure 1. etoposide induced DNA damage in more than 80% of the cells. The number of positive cells after treatment with aclarubicin was considerably lower. One advantage of the comet assay is the possibility of examining the nuclei and the resulting comet tails morphologically. In Figure 3 , the typical appearance of comets 21 h after a 3-hour treatment is shown. After incubation with aclarubicin, the nuclei were significantly larger than after treatment with etoposide or daunorubicin (diameter of nuclei after etoposide, 0.74 ± 0.08 m; daunorubicin 0.68 ± 0.1 m; aclarubicin 2.94 ± 0.20 m). Moreover, the patterns of the comets are distinct for the different drugs; the comet tails after aclarubicin treatment are much more granular, than the comet tails after etoposide or daunorubicin treatment.
None of the topo II inhibitors increased the expression of the CD95 receptor more than 20% as compared to the control, which is consistent with the literature (McGahon).
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Discussion
In this paper, the molecular effects of the topo II inhibitors etoposide, daunorubicin and aclarubicin in a sensitive and a resistant human myeloid cell line have been examined. The most intriguing result is that we did not find notable differences in the DNA damage 24 h after treatment with the same drug concentrations, although HL-60 cells are much more sensitive than KG-1 cells (Figure 2 ). In addition, aclarubicin, which causes considerably less DNA damage than daunorubicin or etoposide, is also a strong initiator of apoptosis. It seems that the drug-induced DNA damage does not correlate with apoptosis.
In Table 4 , the DNA binding rate of topo II inhibitors in intact HL-60 cells and KG-1 cells is shown. As expected, etoposide does not bind to DNA. Daunorubicin and aclarubicin are both strong intercalators with high DNA binding rates. The DNA binding of daunorubicin was 15.48% higher in the more sensitive HL-60 cells. We did not find these differences for aclarubicin. The higher DNA binding of daunorubicin in HL-60 cells could well be one of the factors for the higher sensi- tivity of these cells as we have shown previously that a positive and linear correlation between the DNA binding of daunorubicin and the rate of apoptosis exists.
1 This is not the case for aclarubicin where the binding was more than 90% in both cell lines.
The decisive differences between the cell lines were found within the topo II activities. The total topo II activity in nuclear extracts could be separated in a free and a DNA-bound portion. 21, 22 In order to be active and process DNA, the enzyme must bind to the DNA. 20, 23, 24 As shown in Table 5 , the total topo II activity of KG-1 cells is about 50% of the activity of HL-60 cells. Moreover, only 0.32% of the total activity is bound to the DNA in KG-1 cells. As this is the only topoisomerases portion that can be effectively inhibited by the drugs, these variances might well explain the difference in the sensitivity of the cells to topo II inhibitors. One of the reasons for the higher topo II activity in HL-60 cells is their higher proliferation rate with a doubling time of 22.2 h compared to 64.1 h for KG-1 cells (Table 1) .
At least two reasons can be discussed for the discrepancy of lower topo II activity in untreated KG-1 cells with similar DNA damage after treatment. One of them is the accumulation of DNA strand breaks during drug treatment. With the aim to monitor the trapping of topo II to the DNA by the drugs during the treatment period, we performed the experiments shown in Figure 1 . Drug treatment results in a considerable shift from the free topo II fraction towards the DNA-bound fraction. This is true for both cell lines, although to a higher extent for daunorubicin in HL-60 cells. The larger DNA bound fraction after treatment of KG-1 cells with aclarubicin which does not induce the formation of a 'cleavable complex', might reflect an unspecific activation of topo II by drug treatment.
A second reason is the sensitivity of the single cell microgel electrophoresis assay ('comet assay') which has been used to quantify the DNA damage. This assay allows the combination of morphological examination of the nuclei and the quantification of DNA damage. Under the conditions we used, with a pH of the clectrophoresis buffer Ͼ12.5, DNA single-strand breaks, as well as DNA double-strand breaks are detected. 25, 26 In contrast to the epipodophyllotoxins, anthracyclines are able to induce DNA damage in several ways in addition to the inhibition of topo II. One of them is the intracellular production of free oxygen radicals, which had been held responsible for the cumulative cardiotoxicity of anthracyclines.
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Although we did not examine the nature of DNA damage in this project (eg single-or double-strand breaks, protein associated or not, etc), the composition of DNA damage induced by the different drugs as displayed in Figure 2 are distinct. Classical anthracyclines, such as daunorubicin, induce both topo II associated DNA damage and damage due to free oxygen radicals. Aclarubicin also produces free oxygen radicals but its action does not result in protein associated DNA damage. Etoposide does not produce free oxygen radicals and all DNA damage should arise from topo II inhibition. The morphological appearance of the nuclei and their comet tails are distinct for the various drugs (Figure 3 ). This might be explained by their different modes of intracellular action. Etoposide and daunorubicin induce small apoptotic nuclei with long tails. Treatment with aclarubicin results in a swelling of the nuclei and a more granular pattern of the DNA tail. This might be explained by the inhibition of topo II action without the formation of a 'cleavable complex' by aclarubicin that results in the inability of the cell to supercoil DNA.
The knowledge of intracellular effects and specific apoptotic signals of topo II inhibitors is mandatory for the future design of efficacious therapeutic strategies. Evidently, the nuclear topo II activity is a suitable marker for the cellular sensitivity to topo II inhibitors. Further studies are necessary to decide whether these in vitro data are compatible with the clinical situation.
